PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

E MA	Application Number	10/571,414
TRANSMITTAL	Filing Date	MARCH 10, 2006
FORM	First Named Inventor	FRANK THEOBALD
	Art Unit	1516
TA TRADE	Examiner Name	
Total Number of Pages in This Submission	9 Attorney Docket Number	R04209US (#90568)
	ENCLOSURES (Check al	li that apply)
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on Converting Converses on	After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter X Other Enclosure(s) (please Identify below): Return post card LETTER W/ENGLISH TRANSLATION OF IPRP
SIGNA	TURE OF APPLICANT, ATT	ORNEY, OR AGENT
Firm Name D. Peter Hochber		
Signature	7	
Printed name D. Peter Hochbe	rg	
Date Shuby	17,2007	Reg. No. 24,603
C	ERTIFICATE OF TRANSMIS	SSION/MAILING
I hereby certify that this correspondence is sufficient postage as first class mail in an er the date shown below:	being facsimile transmitted to the US nvelope addressed to: Commissioner	SPTO or deposited with the United States Postal Service with r for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on
Signature	Time Roban	
Typed or printed name Christine		Date 1/17/2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Frank Theobald et al.

Serial No.:

10/571,414

Filed:

March 10, 2006 / Conf. No. 3449

Title:

MEDICAL SKIN PATCHES WITH A CONTENT OF ESSENTIAL OILS FOR TREATING COLDS, AND PROCESSES FOR THEIR

PRODUCTION

Examiner:

/ Art Unit: 1615

Attorney File:

RO4209US (#90568)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-4150

LETTER

Sir:

For inclusion in the record of the referenced patent application is an English translation of the "International Preliminary Report on Patentability" as rendered with respect to PCT/EP2004/010046 from which this is a 371 application.

Respectfully submitted,

By:

D. Peter Hochberg

Reg. No. 24,603

Certificate of Mailing

I hereby certify that this document, and anything indicated as being attached or enclosed, is being deposited with the United States Postal Service as First Class mail in an envelope addressed: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date noted below.

Christine Kotran: (

D. Peter Hochberg Co., L.P.A. 1940 E. 6th Street - 6TH Floor

Cleveland, Ohio 44114

Phone: (216) 771-3800

Fax: (216) 771-3804

DPH/SM/ck

Enc.

e-mail: DPHDOCKET@aol.com

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF TRANSMITTAL
OF COPIES OF TRANSLATION
OF THE INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY
(CHAPTER I OR CHAPTER II
OF THE PATENT COOPERATION TREATY)

(PCT Rules 44bis.3(c) and 72.2)

Γο:	
	Eingegangen
FLACCUS, Rolf-Die Bussardweg 10 50389 Wesseling ALLEMAGNE	ter 1 7. AUG. 2006
•	FRIST:

Date of mailing (day/month/year)
03 August 2006 (03.08.2006)

Applicant's or agent's file reference
LTS 2003/007 PCT

International application No.
PCT/EP2004/010046

Applicant

LTS LOHMANN THERAPIE-SYSTEME AG et al

L.	Transmittal of the translation to the applicant		

The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter I).

The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter II).

2. Transmittal of the copy of the translation to the designated or elected Offices.

The International Bureau notifies the applicant that copies of that translation have been transmitted to the following designated or elected Offices requiring such translation:

KR

The following designated or elected Offices, having waived the requirement for such a transmittal at this time, will receive copies of that translation from the International Bureau only upon their request:

AE, AG, AL, AM, AP, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EA, EC, EE, EG, EP, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OA, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

3. Reminder regarding translation into (one of) the official language(s) of the elected Office(s).

The applicant is reminded that, where a translation-of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability (Chapter II).

It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned within the applicable time limit (Rule 74.1). See Volume II of the PCT Applicant's Guide for further details.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Agnes Wittmann-Regis

Facsimile No. +41 22 338 82 70

Facsimile No. +41 22 338 82 70 Form PCT/IB/338 (January 2004)

PATENT COOPERATION TREATY

TRANSLATION INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or age	nt's file reference					
	3/007 PCT	FOR FURTHER AC		See Form PCT/IPEA/416		
International appli	cation No.	International filing date	: (day/month/year)	Priority date (day/month/year)		
PCT/EP20	004/010046	09.09.2004		11.09.2003		
l	nt Classification (IPC) or nati					
A61K9/70, A619/00, A61L15/44, A61L15/16, A61F13/02						
Applicant						
l	MANN THERAPIE-	-SYSTEME AG				
	port is the international prelimities 35 and transmitted to the			international Preliminary Examining Authority		
1	PORT consists of a total of		sheets, including	g this cover sheet.		
1	oort is also accompanied by A					
	1					
а	(sent to the applicant and					
	sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).					
	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental					
	Box.					
b. L_	(sent to the International	Bureau only) a total of (indicate type and numbe	er of electronic carrier(s))		
	related thereto, in compute Section 802 of the Adminis		s indicated in the Supple	containing a sequence listing and/or tables emental Box Relating to Sequence Listing (see		
4. This re	port contains indications relat					
	_	ing to the following heli				
	Box No. I Basis of th	e report				
	Box No. II Priority					
	Box No. III Non-establ	lishment of opinion with	regard to novelty, inven	tive step and industrial applicability		
	Box No. IV Lack of un	nity of invention				
	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability: citations and explanations supporting such statement					
	Box No. VI Certain do	ocuments cited				
Box No. VII Certain defects in the international application						
	Box No. VIII Certain observations on the international application					
Date of submiss	ion of the demand		Date of completion of t	his report		
			_	•		
Name and maili	ng address of the IPEA/EP		Authorized officer			
Jr			m 1 1 21			

International application No.

PCT/EP2004/010046

Box No. I Basis of the report				
 With regard to the language, this report is based on the international application in the indicated under this item. 	language in which it was filed, unless otherwise			
This report is based on translations from the original language into the following which is the language of a translation furnished for the purposes of:	language			
international search (Rule 12.3 and 23.1(b))				
publication of the international application (Rule 12.4)				
international preliminary examination (Rule 55.2 and/or 55.3)				
With regard to the elements of the international application, this report is based on (r receiving Office in response to an invitation under Article 14 are referred to in this this report):	eplacement sheets which have been furnished to the report as "originally filed" and are not annexed to			
the international application as originally filed/furnished				
the description:				
pages 1-12	as originally filed/furnished			
pages* received by this Ac	uthority on			
pages* received by this At	othority on			
the claims:				
nos. <u>1-24</u>	as originally filed/furnished			
nos.* as amer	nded (together with any statement) under Article 19			
nos.* received by this A	uthority on			
nos.* received by this A	uthority on			
the drawings:				
sheets	as originally filed/furnished			
sheets* received by this A	uthority on			
sheets* received by this A	uthority on			
a sequence listing and/or any related table(s) – see Supplemental Box Relating t	o Sequence Listing.			
3. The amendments have resulted in the cancellation of:	•			
the description, pages				
the claims, nos.				
the drawings, sheets/figs				
the sequence listing (specify):				
This report has been established as if (some of) the amendments annexed to t they have been considered to go beyond the disclosure as filed, as indicated in t	his report and listed below had not been made, since			
the description, pages				
the claims, nos.				
the drawings. sheets/figs				
the sequence listing (specify):				
any table(s) related to sequence listing (specify):				
# If item 4 applies, some or all of those sheets may be marked "superseded."				

International application No.
PCT/EP2004/010046

Box			icle 35(2) with regard to novelty, inventive step or industrial applicability; porting such statement	
1.	Statement			
	Novelty (N)	Claims	4, 14, 15, 22, 23	YES
		Claims	1-3, 5-13, 16-21, 24	NO
	Inventive step (IS)	Claims		YES
		Claims	1-24	NO
	Industrial applicability (IA)	Claims	1-24	YES
		Claims		NO

- 2. Citations and explanations (Rule 70.7)
 - The present report makes reference to the following documents:
 - D1: WO 01/78691A (LECTEC CORP; GOON DAVID J W (US); ROLF DAVID (US))
 - 25 October 2001 (2001-10-25)
 - D2: US 6 090 403 A (BLOCK LESLIE L ET AL)
 18 July 2000 (2000-07-18)
 - D3: WO 01/89475 A.

2. Novelty

The present application fails to satisfy the requirements of PCT Article 33(1) because the subject matter of the claims lacks novelty (PCT Article 33(2)).

2.1 Document D1 discloses a therapeutic patch consisting of a porous backing layer and a therapeutic formulation containing a medicament, a support for said medicament, and a pressuresensitive adhesive material (see D1, page 2, line 27 to page 3, line 3). The medicament is

/...

International application No.
PCT/EP2004/010046

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

an antitussive, for example camphor, menthol, eucalyptus oil, thyme oil (see D1, page 6, line 24 to page 7, line 2), the polymer support is preferably karaya rubber (see D1, page 13, lines 10-20) and the adhesive may be, *inter alia*, a polyacrylate (see D1, page 13, lines 10-20).

D1 discloses a number of formulations that contain less than 5 wt.% of water. Formulations that contain 0 wt.% of water are also described. The patch used in the case of coughs can be stuck to the chest, neck, chin or upper lip such that the medicaments can be inhaled (see D1, page 17, lines 18-25).

2.2 Documents D2 and D3 describe patches in which the support is coated with a hydrophilic formulation for pressure-sensitive bonding, said formulation containing volatile oils. A composition in the form of an unguent is mentioned in D2 (see column 8) and D3 (see page 17), which composition consists of camphor, menthol, eucalyptus oil, glycerine, karaya rubber and a latex adhesive and can be applied to a support without dilution.

Since the sum of the components of the unguent is 100 wt.%, and since the unguent can be applied to the support without further dilution, it can be assumed that the water content of the unguent is very small.

/ . . .

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Said unguent is produced by mixing the components in the presence of water or of a non-polar solvent, the latter being preferred (see D2, column 7, lines 50-60; D3, page 16, lines 17-19). The patch is used for disorders such as the common cold, a soothing effect being produced by the inhalation of the aromatic oils.

Thus, documents D1, D2 and D3 anticipate the novelty of claims 1-3, 5-13, 16-21 and 24.

3 Inventive step

The present application describes medical skin patches constituting hydrophilic, topical, anhydrous systems that are suitable for the delivery of volatile oils and are used for the treatment of disorders such as the common cold.

Although patches of this type have already been described in the prior art, coating compounds such as those according to claims 22 and 23 of the application have not been mentioned. Since said coating compounds differ from the formulations according to the prior art only by virtue of the quantity or concentration of the components used, and in the absence of any disclosure of a surprising technical effect that might be attributable to the use of different quantities, claims 22 and 23 are considered to be an obvious variation and modification of known formulations.

International application No.
PCT/EP2004/010046

Box No. V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

The method parameters specified in claims 14 and 15 are not mentioned in the prior art. The temperature variation is normal in the development of a new method. Adjusting the pot life, which - as stated in the application - is dependent on the water content of the coating compound, is also a routine measure.

Thus, the application does not involve an inventive step within the meaning of PCT Article 33(3).